1. ABOUT THE DATASET -------------------- Title: A factorial randomised trial investigating factors influencing general practitioners’ willingness to prescribe aspirin for cancer preventive therapy in Lynch syndrome: a registered report Creator(s): Kelly E. Lloyd, Louise H. Hall, Lucy Ziegler, Robbie Foy, Gillian M. Borthwick, Mairead MacKenzie, David G. Taylor, and Samuel G. Smith on behalf of the AsCaP group. Organisation(s): K E Lloyd: MA, PhD student, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. ORCID: 0000-0002-0420-2342. L H Hall: PhD, research fellow, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. ORCID: 0000-0001-9032-4540. L Ziegler: PhD, professor of palliative care, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. ORCID: 0000-0001-9563-5014. R Foy: PhD, MRCGP, MFPHM, clinical professor of primary care, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. ORCID: 0000-0003-0605-7713. G M Borthwick: PhD, Cancer Prevention Programme manager, Translational and Clinical Research Institute, Newcastle University, Newcastle, UK. ORCID: 0000-0003-1143-7374 M MacKenzie: Trustee, Independent Cancer Patients’ Voice (ICPV). D G Taylor: BSc, emeritus professor of pharmaceutical and public health policy, School of Pharmacy, UCL, London, UK. ORCID: 0000-0003-0679-1467. S G Smith: PhD, associate professor, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. ORCID: 0000-0003-1983-4470. Rights-holder(s): Publication Year: 2022 Description: We investigated the optimal type and level of information to communicate with GPs to increase willingness to prescribe aspirin for colorectal cancer prevention. We recruited GPs in England and Wales (n=672) to an online survey with a 2 by 3 factorial design. GPs were randomised to one of eight vignettes describing a hypothetical patient with Lynch syndrome recommended to take aspirin by a clinical geneticist. Across the vignettes, we manipulated the presence or absence of three types of information: 1) existence of NICE guidance; 2) results from the CAPP2 trial; 3) information comparing risks/benefits of aspirin. We estimated the main effects and all interactions on the primary (willingness to prescribe) and secondary outcomes (comfort discussing aspirin). Cite as: Kelly E. Lloyd, Louise H. Hall, Lucy Ziegler, Robbie Foy, Gillian M. Borthwick, Mairead MacKenzie, David G. Taylor, and Samuel G. Smith on behalf of the AsCaP group. (2022): A factorial randomised trial investigating factors influencing general practitioners’ willingness to prescribe aspirin for cancer preventive therapy in Lynch syndrome: a registered report. University of Leeds. [Dataset] [DOI] Related publication: K.E. Lloyd, L.H. Hall, L.Ziegler, R.Foy, G.M.Borthwick, M. MacKenzie, D.G. Taylor, and S.G. Smith on behalf of the AsCaP group. A factorial randomised trial investigating factors influencing general practitioners’ willingness to prescribe aspirin for cancer preventive therapy in Lynch syndrome: a registered report. British Journal of General Practice. In preparation. Contact: Kelly E. Lloyd, Leeds Institute of Health Science, University of Leeds, Clarendon Way, Leeds, LS2 9NL, UK. Email: umkel@leeds.ac.uk 2. TERMS OF USE --------------- [A standard copyright notice and licence statement with URL can be used, e.g. Copyright [publication year] [name of rights-holder(s)]. This dataset is licensed under a Creative Commons Attribution 4.0 International Licence: https://creativecommons.org/licenses/by/4.0/.] 3. PROJECT AND FUNDING INFORMATION ---------------------------------- Title: Aspirin for Cancer Prevention (AsCaP) Dates: 2018 Funding organisation: This work is fully funded by the Aspirin for Cancer Prevention AsCaP Group CRUK Grant Code: A24991, Senior Executive Board Prof. J Burn, Prof. A.T Chan, Prof. J Cuzick, Dr. B Nedjai, Prof. Ruth Langley. KEL is supported by an Economic and Social Research Council studentship [grant number ES/P000745/1]. This report is independent research supported by the National Institute for Health Research NIHR Advanced Fellowship, Dr Samuel Smith, [grant number NIHR300588]. SGS also acknowledges funding support from a Yorkshire Cancer Research University Academic Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Grant no.: 4. CONTENTS ----------- File listing Folder: Study_materials Files: GP_PIS_V.2_07.06.21.docx - The participant information sheet provided to all participants. GP_survey_consent_form_V2_28.05.21.docx - The consent form completed by all participants. Factorial_randomisation_order.docx - Description of the eight experimental conditions (i.e. vignettes) in the study, and the three factors across the conditions. Aspirin GP Questionnaire V.7_18.10.21_routing.docx - The survey used in the study. Vignettes.20.10.21.docx - The vignettes (i.e. case studies) used in the study. Folder: R_scripts Files: GP_data_cleaning.R - R script for cleaning the raw data. GP_data_analysis.R - R script for analysing the raw data. Folder: Raw_data File: GP_survey_full_05.05.22 - The raw dataset without the R scripts applied to it. Folder: Clean_data File: GP_Data_Cleaned8.csv - Final cleaned dataset, which is the raw dataset after all R scripts have been applied to it. README_Lloyd_2022.txt - Basic set of information to be provided about your dataset. 5. METHODS ---------- We preregistered the stage one registered report, with full details on the study methods, on Open Science Framework (https://doi.org/10.17605/OSF.IO/B5SFH).